natgillin/translations-raw huggingface dataset:
Method failure: 0.40 (upper limit 95 % confidence interval 1.03)
Neuspešnost metode: 0,40 (zgornja meja 95 % intervala zaupanja 1,03)
Method failure: 1.22 (upper limit 95 % confidence interval 2.18)
Neuspešnost metode: 1,22 (zgornja meja 95 % intervala zaupanja 2,18)
METHOD OF ADMINISTRATION
25 (12%)a
METHOD OF ADMINISTRATION
25 (69,4%)a
METHOD OF ADMINISTRATION
AÐFERÐ VIÐ LYFJAGJÖF
METHOD OF ADMINISTRATION
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Method of administration
Lyfjagjöf
Method of administration
Navodila o načinu dajanja zdravila
METHOD OF ADMINISTRATION
NAČIN UPORABE
Method of administration
Način dajanja
Method of administration
Način dajanja zdravila
Method of administration
Način jemanja
Method of administration
Način uporabe:
Method of administration
Odmerjanje
Method of administration
Odmerjanje in način uporabe
METHOD OF ADMINISTRATION
POSTOPE UPORABE
Method of administration
Postopek aplikacije
METHOD OF ADMINISTRATION
POSTOPEK IN NAČIN UPORABE ZDRAVILA
METHOD OF ADMINISTRATION
POSTOPEK IN POT(I) UPORABE ZDRAVILA
METHOD OF ADMINISTRATION
POSTOPEK UPORABE ZDRAVILA
METHOD OF ADMINISTRATION
POSTOPEK UPORABE.
METHOD OF ADMINISTRATION
POT UPORABE
Method of administration ( pVTEp orthopaedic surgery , SPAF, DVT/PE)
Način uporabe (pVTEp pri ortopedski operaciji, SPAF, GVT/PE)
Method of administration (pVTEp orthopaedic surgery)
Način uporabe (pVTEp pri ortopedski operaciji)
Method of administration (SPAF, DVT/PE)
Način uporabe (SPAF, GVT/PE)
Method of administration For implantation.
Način uporabe za implantiranje
Method of administration For intravenous use.
Način uporabe za intravensko uporabo
Method of administration For ocular use.
Način uporabe za okularno uporabo
Method of administration For oral use.
Način uporabe za peroralno uporabo
Method of administration For subcutaneous use.
Način uporabe za subkutano uporabo
Method of administration Intravenous use.
Način uporabe Intravenska uporaba
Method of administration Oral administration.
Način uporabe peroralna uporaba
Method of administration Oral use
Način uporabe peroralna uporaba
Method of administration Oral use
Način uporabe Peroralna uporaba.
Method of administration Oral use.
Način uporabe
Method of administration Oral use.
Načinuporabe peroralna uporaba
Method of administration Subcutaneous use.
Način uporabe Subkutana uporaba.
Method of administration:
Način dajanja
Method of administration:
Način uporabe
METHOD OF ADMINSTRATION
POSTOPEK UPORABE
Method of preparation
Postopek priprave
Method of titration
Način titriranja
Method used for assessment (e.g.
Metoda, uporabljena za oceno (npr.
METHOD(S) AND ROUTES OF ADMINISTRATION
NAČIN IN POT(I) UPORABE
Methodof administration
Način uporabe
METHODS AND ROUTE OF ADMINISTRATION
NAČIN IN POT(I) UPORABE
METHODS AND ROUTE(S) OF ADMINISTRATION
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Methotrexate (20 mg/m2/week, PO): days 8, 15, 22, 29, 36, 43, 50
metotreksat (20 mg/m2/teden, peroralno): 8., 15., 22., 29., 36., 43. in 50. dan
Methotrexate (5 g/m2 over 24 hours, IV): day 1
metotreksat (5 g/m2 v času 24 ur, i.v.): 1. dan
Methotrexate (5 g/m2 over 24 hours, IV): days 1 and 15
metotreksat (5 g/m2 v času 24 ur, i.v.): 1. in 15. dan
Methotrexate (5 g/m2 over 24 hours, IV): days 1 and 15 Leucovorin (75 mg/m2 at hour 36, IV; 15 mg/m2 IV or PO q6h x 6
metotreksat (5 g/m2 v času 24 ur, i.v.): 1. in 15. dan
Methotrexate (MTX) naïve populations with rheumatoid arthritis
Bolniki z revmatoidnim artritisom, ki še niso prejemali metotreksata
Methotrexate (n = 258 cycles)
metotreksat (n = 258 krogov)
Methotrexate (used to treat cancer and rheumatic disorders)
metotreksat (uporablja se za zdravljenje raka in revmatskih bolezni)
methotrexate (used to treat cancer or rheumatoid arthritis)
metotreksat (za zdravljenje raka ali revmatoidnega artritisa)
methotrexate (used to treat e.g. rheumatoid arthritis)
metotreksat (uporablja se za zdravljenje npr. revmatoidnega artritisa),
Methotrexate (used to treat rheumatoid arthritis, psoriasis and leukaemia)
metotreksat (uporablja se za zdravljenje revmatoidnega artritisa, psoriaze in levkemije)
Methotrexate and cytarabine can interfere differently: prior administration of these substances can increase the action of Oncaspar synergistically.
Metotreksat in citarabin lahko povzročita različno medsebojno delovanje: predhodno dajanje teh učinkovin lahko sinergistično poveča delovanje zdravila Oncaspar.
Methotrexate Enbrel
metotreksat Enbrel
Methotrexate is continued while using Cimzia.
Metotreksat bolniki med uporabo zdravila Cimzia jemljejo naprej.
methotrexate, a medicine typically used to treat cancer
metotreksat, zdravilo, ki se običajno uporablja za zdravljenje raka
methotrexate, a medicine used to treat severe joint disease (rheumatoid arthritis) or skin disease (psoriasis),
metotreksat, zdravilo za zdravljenje hude bolezni sklepov (revmatoidnega artritisa) ali bolezni kože (luskavice),
Methotrexate-Naive
Brez predhodnega zdravljenja z metotreksatom
Methotrexate:
Metotreksat:
methotrexate: a medicine to treat rheumatoid arthritis, cancer and the skin disease, psoriasis
metotreksat: zdravilo za zdravljenje revmatoidnega artritisa, raka in kožne bolezni luskavice (psoriaze),
methotrexate: a medicine to treat severe joint inflammation (rheumatoid arthritis), cancer and the skin disease psoriasis.
metotreksat: zdravilo za zdravljenje hudega vnetja sklepov (revmatoidni artritis), raka in kožne bolezni luskavice
Methotrexate: no dose adjustment required.
Metotreksat: prilagoditev odmerka ni potrebna.
methoxy polyethylene glycol-epoetin beta
metoksipolietilenglikol epoetin beta
Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Benzyl alcohol
Metilparahidroksibenzoat (E218) Propilparahidroksibenzoat (E216) Benzilalkohol
Methyl parahydroxybenzoate  0.8 mg/ml.
Metilparahidroksibenzoat  0.8 mg/ml.
Methylcellulose
metilceluloza
Methyldopa There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.
metildopa Pri sočasni uporabi hidroklorotiazida in metildope so poročali o posameznih primerih hemolitične anemije.
methylergonovine is
ergotamina ali metilergonovina je
methylergonovine)
tioridazin
Methylnaltrexone bromide is less able to enter the brain than naltrexone, meaning that it blocks the mu-opioid receptors in the gut but not in the brain.
Metilnaltreksonijev bromid slabše prehaja v možgane kot naltrekson, kar pomeni, da zavira mu-opioidne receptorje v črevesju, ne pa tudi v možganih.
Methylnaltrexone bromide should be used with caution in patients with known or suspected lesions of the GI tract.
Metilnaltreksonijev bromid je treba pri bolnikih z znano lezijo prebavil ali sumom nanjo uporabljati previdno.
Methylnaltrexone bromide should not be used during pregnancy unless clearly necessary.
Metilnaltreksonijevega bromida ne smete uporabljati med nosečnostjo, razen če je nujno potrebno.
Methylnaltrexone bromide treatment has not been studied in adult patients with advanced illness in clinical trials for longer than 4 months, and should therefore only be used for a limited period (see section 5.1).
Zdravljenja z metilnaltreksonijevim bromidom niso preučili pri odraslih bolnikih v kliničnih preskušanjih, daljših od 4 mesecev, zato ga je treba uporabljati le za omejeno obdobje (glejte poglavje 5.1).
Methylnaltrexone bromide-treated patients had a higher rate of laxation within 4 hours of the first dose (48 %) than placebo-treated patients (16 %); p<0.0001. Methylnaltrexone bromide-treated patients also had significantly higher rates of laxation within
Bolniki, zdravljeni z metilnaltreksonijevim bromidom, so pogosteje odvajali v 4 urah po prvem odmerku (48 %) kot bolniki, ki so prejemali placebo (16 %); p<0,0001.
Methylparahydroxybenzoate which may cause allergic reactions (possibly delayed).
metilparahidroksibenzoat, ki lahko povzroči alergijske reakcije (lahko zapoznele).
Methylphenidate
metilfenidat
methylphenidate (used to treat hyperactivity in children and narcolepsy (excessive sleepiness))
metilfenidat (za zdravljenje hiperaktivnosti pri otrocih in narkolepsije (pretiranespečnosti)
Methylprednisolone 40 mg intrathecal, days 1, 8, 15, 22
metilprednizolon 40 mg intratekalno, 1., 8., 15., 22. dan
Methylthioninium chloride has moderate influence on the ability to drive and use machines.
Zdravilo Metiltioninijev klorid ima zmeren vpliv na sposobnost vožnje in upravljanja strojev.
Methylthioninium chloride is a potent inhibitor of the transporters OCT2, MATE1 and MATE2-K.
Metiltioninijev klorid je močan zaviralec prenašalcev OCT2, MATE1 in MATE2-K.
Methylthioninium chloride Proveblue 5 mg/ml solution for injection methylthioninium chloride
Metiltioninijev klorid Proveblue 5 mg/ml raztopina za injiciranje metiltioninijev klorid
Methylthioninium chloride Proveblue is a solution for injection that contains the active substance methylthioninium chloride (5 mg/ml).
Zdravilo Metiltioninijev klorid Proveblue je raztopina za injiciranje, ki vsebuje zdravilno učinkovino metiltioninijev klorid (5 mg/ml).
Methylthioninium chloride Proveblue is a ‘hybrid generic medicine’.
Zdravilo Metiltioninijev klorid Proveblue je „hibridno generično zdravilo“.
Methylthioninium chloride Proveblue is hypotonic and may be diluted in 50 ml glucose 50 mg/ml (5%) solution for injection to avoid local pain, in particular in paediatric population.
Zdravilo Metiltioninijev klorid Proveblue je hipotonično in se ga lahko razredči v 50 ml raztopine glukoze 50 mg/ml (5 %) za injiciranje, da se izognemo lokalni bolečini, zlasti pri pediatrični populaciji.
Methylthioninium chloride Proveblue is used in adults and children of all ages as an antidote to treat symptoms of methaemoglobinaemia caused by exposure to medicines or chemicals.
Zdravilo Metiltioninijev klorid Proveblue se uporablja pri odraslih in otrocih vseh starosti kot antidot za zdravljenje simptomov methemoglobinemije, ki jo povzroča izpostavljenost zdravilom ali kemikalijam.
Methylthioninium chloride Proveblue will be given to you or your child (0-17 years old) to treat problems with your blood resulting from exposure to some medicines or chemicals that can cause a disease called methaemoglobinaemia.
Zdravilo Metiltioninijev klorid Proveblue boste vi ali vaš otrok (0–17 let starosti) prejeli za zdravljenje problemov s krvjo, ki so posledica izpostavljenosti nekaterim zdravilom ali kemikalijam, ki lahko povzročijo bolezen, imenovano methemoglobinemija.
Methylthioninium chloride should be avoided in patients receiving medicinal products that enhance serotonergic transmission including SSRIs (selective serotonin reuptake inhibitors), bupropion, buspirone, clomipramine, mirtazapine, and venlafaxine.
Metiltioninijevemu kloridu se je treba izogniti pri bolnikih, ki prejemajo zdravila, ki povečujejo serotonergični prenos, vključno s SSRI (selektivnimi zaviralci ponovnega privzema serotonina), burpropionom, buspironom, klomipraminom, mirtazapinom in venlafaksinom.
Metoclopramide – used to treat feelings of sickness (nausea) and vomiting, including in patients with migraine
metoklopramid – uporablja se za zdravljenje občutka slabosti (navzea) in bruhanja, vključno pri bolnikih z migrenami; glicerin trinitrat (GTN, nitroglicerin), izosorbid mononitrat, eritritil tetranitrat, pentaeritritol
metoprolol (for heart disorders)
metoprolol (za srčne motnje),
Metoprolol (given in heart
Metoprolol (pri srčnem
metoprolol (used to treat heart failure)
metoprolol (za zdravljenje srčnega popuščanja),
metoprolol – used to lower blood pressure and/or reduce heart rate
metoprolol – uporablja se za zniževanje krvnega tlaka in/ali srčnega utripa
metronidazole (used to treat infections)
metronidazol (za zdravljenje okužb),
Metrorrhagia
bolečine v okončinah
Metrorrhagia
metroragija
metrorrhagia, menorrhagia, breast pain, pelvic pain
metroragija, menoragija, bolečine v dojkah, bolečine v medenici
mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia); zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system);
meksiletin (za zdravljenje neenakomernega bitja srca, stanje poznano kot ventrikularna aritmija), zidovudin (zdravilo, ki ga lahko uporabljamo za zdravljenje sindroma pridobljene imunske pomanjkljivosti (AIDS), bolezni imunskega sistema pri človeku),
mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia); zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system);
meksiletin (za zdravljenje neenakomernega bitja srca, stanje poznano kot ventrikularna aritmija); zidovudin (zdravilo, ki ga lahko uporabljamo za zdravljenje sindroma pridobljene imunske pomanjkljivosti (AIDS), bolezni imunskega sistema pri človeku);
mg
mgc
mg + 7 x 20 mg tablets
7 x 15 mg + 7 x 20 mg tablet
mg corresponding to 5 drops.
mg ustreza 5 kapljicam.
mg emodepside, 15 mg praziquantel.
emodepsid 3 mg, prazikvantel 15 mg
mg every other week.
20 mg vsak teden.
mg of selamectin dispensed
Selamektin v mg
mg once daily
g enkrat na dan
mg once daily
ombitasvir/p
mg per kg = mg for each kilogram of the infant’s body weight.
mg na kg = mg za vsak kilogram dojenčkove telesne mase.
mg sachets
mg vrečice
mg single dose)
enkratni odmerek)
mg single dose)/
(50 mg enkratni odmerek)/grazoprevir
mg teduglutide powder in vial (glass) with rubber stopper (bromobutyl).
mg teduglutida v obliki praška v viali (steklo) z gumijastim zamaškom (bromobutil).
mg vials:
mg viale:
mg. administered
Odmerek v mg
mg/200 mg 175 mg /
Levodopa/Carbidopa/ Entacapone Orion
mg/dL)
(mediana, mg/dl)
mg/kg body weight dose per day
mg/kg telesne mase dnevni odmerek
mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and weeks after the first infusion, then every 6 to 8 weeks.
Odmerek je 5 mg/kg v intravenski infuziji, čemur naj sledita dodatni infuziji z odmerkoma 5 mg/kg 2 in 6 tednov po prvi infuziji, potem pa na vsakih 6 do 8 tednov.
mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and weeks after the first infusion, then every 8 weeks thereafter.
Odmerek je 5 mg/kg v obliki intravenske infuzije, čemur naj sledita dve infuziji v odmerku 5 mg/kg 2 in 6 tednov po prvi infuziji, potem pa na vsakih 8 tednov.
mg/kg range
mg/kg obseg
mg/ml
raztopina
MGIT® Mycobacterium growth indicator tube liquid media system n= subjects with SCC at 2 months
MGIT® – tekoče gojišče v epruveti kot pokazatelj rasti mikobakterije n= osebe s SCC pri 2 mesecih
MI (excl. silent MI)b
MI (izključujoč nemi MI)b
MI was identified per the CK-MB core laboratory criteria.
Miokardni infarkt so ugotavljali na podlagi osrednjih laboratorijskih meril za CK-MB.
mibefradil, diltiazem and verapamil, used to lower blood pressure in people with high blood pressure. ritonavir, lopinavir/ritonavir, indinavir, nelfinavir, saquinavir, atazanavir, amprenavir, fosamprenavir and darunavir, used to treat human immunodeficiency virus (HIV)/AIDS. boceprevir and telaprevir, used to treat hepatitis C.
mibefradil, diltiazem in verapamil, ki se uporabljajo za zniževanje krvnega tlaka pri ljudeh z zvišanim krvnim tlakom ritonavir, lopinavir/ritonavir, indinavir, nelfinavir, sakvinavir, atazanavir, amprenavir, fosamprenavir in darunavir, ki se uporabljajo za zdravljenje okužbe z virusom humane imunske pomanjkljivosti (HIV)/AIDS-a boceprevir in telaprevir, ki se uporabljata za zdravljenje hepatitisa C
MIC (Range) (µg/ml)
MIC (vrednosti) (μg/ml)
MIC breakpoint (mg/L)
mejna vrednost MIC (mg/l)
MIC breakpoint (mg/L)
Mejna vrednost MIK (mg/l)
MIC breakpoint (µg/ml)
Prelomne točke MIK (µg/ml)
MIC breakpoints (mg/L)
Mejne vrednosti MIC (mg/l)
MIC increases observed were in large part reversible during off- treatment periods.
Zvišanje MIK je večinoma izzvenelo v vmesnih obdobjih brez zdravljenja.
MIC of wild-type population(µg/ml)
MIC pri bakterijah divjega tipa (µg/ml)
MIC values for Salmonella were reported to be in the range of 4–16 µg/ml, and all strains were wild type.
Vrednosti MIK za Salmonella so bile v razponu od 4-16 µg/ml in vsi sevi so bili divji.
MIC50
Citrobacter sp.
MIC50 (µg/ml)
MIC50 (μg/ml)
MIC50 (µg/ml)
MIK50 (µg/ml)
MIC90
0.250
MIC90 (µg/ml)
MIC90 (μg/ml)
Micafungin exhibits fungicidal activity against most Candida species and prominently inhibits actively growing hyphae of Aspergillus species.
Mikafungin kaže fungicidno delovanje proti večini vrst Candida in izrazito zavira aktivno rastoče hife vrste Aspergillus.
Micafungin has a low potential for interactions with medicines metabolised via CYP3A mediated pathways.
Mikafungin ima majhen potencial za interakcije z zdravili, ki se presnavljajo s pomočjo encimov CYP3A.
Micafungin has been shown to be metabolised to several compounds; of these M-1 (catechol form), M-2 (methoxy form of M-1) and M-5 (hydroxylation at the side chain) of micafungin have been detected in systemic circulation.
Mikafungin se presnavlja v več spojin; v sistemskem krvnem obtoku so zaznali prisotnost M-1 (v obliki katehola), M-2 (metoksi oblika M-1) in M-5 (hidroksilacija stranske verige).
Micafungin is an intravenously administered medication.
Mikafungin je zdravilo, ki se aplicira intravensko.
Micafungin non-competitively inhibits the synthesis of 1,3--D-glucan, an essential component of the fungal cell wall.
Mikafungin nekompetitivno zavre sintezo 1,3--D-glukana, ki je bistvena sestavina celične stene gliv.
Micafungin treatment was associated with significant impairment of liver function (increase of ALT, AST or total bilirubin > 3 times ULN) in both healthy volunteers and patients.
Zdravljenje z mikafunginom je bilo povezano z značilnim poslabšanjem delovanja jeter (povišanje ALT, AST ali celotni bilirubin > 3-kratnik ULN) tako pri zdravih prostovoljcih kot tudi pri bolnikih.
Micardis 20 mg tablets are white, round and engraved with the code number '50H' on one side and the company logo on the other side.
Tablete Micardis 20 mg so bele, okrogle tablete z vtisnjeno kodno številko 50H na eni in logom podjetja na drugi strani.
Micardis 40 mg tablets are white, oblong-shaped, and engraved with the code number '51H' on one side and the company logo on the other side.
Tablete Micardis 40 mg so bele, podolgovate tablete z vtisnjeno kodno številko 51H na eni in logom podjetja na drugi strani.
Micardis 80 mg tablets are white, oblong-shaped and engraved with the code number '52H' on one side and the company logo on the other side.
Tablete Micardis 80 mg so bele, podolgovate tablete z vtisnjeno kodno številko 52H na eni in logom podjetja na drugi strani.
Micardis is available in blister packs containing 14, 28, 56, or 98 tablets.
Zdravilo Micardis je na voljo v pretisnih omotih po 14, 28, 56 ali 98 tablet.
Micardis is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Zdravilo Micardis v zgodnji nosečnosti ne priporočajo; ne smete pa ga jemati, ko boste noseči več kot 3 mesece, ker lahko po tretjem mesecu nosečnosti resno škoduje vašemu otroku.
Micardis is used to treat essential hypertension (high blood pressure) in adults. ‘Essential’ means that the high blood pressure is not caused by any other condition.
Zdravilo Micardis uporabljamo za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih. 'Esencialna' pomeni, da visokega krvnega tlaka ne povzroča drugo bolezensko stanje.
MicardisPlus 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Micardis 40 mg
Zdravilo MicardisPlus 40 mg/12,5 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno nadzorovati z zdravilom Micardis 40 mg
MicardisPlus 40 mg/12.5 mg tablets are red and white, oval-shaped two-layer tablets engraved with the company logo and the code 'H4'.
Tablete zdravila MicardisPlus 40 mg/12,5 mg so rdeče in bele, ovalne, dvoslojne z vtisnjenim znakom podjetja in kodno številko 'H4'.
MicardisPlus 40 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
MicardisPlus 40 mg /12,5 mg tablete telmisartan/hidroklorotiazid
MicardisPlus 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Micardis 80 mg
Zdravilo MicardisPlus 80 mg/12,5 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno nadzorovati z zdravilom Micardis 80 mg
MicardisPlus 80 mg/12.5 mg tablets are red and white, oval-shaped, two-layer tablets engraved with the company logo and the code 'H8'.
Tablete zdravila MicardisPlus 80 mg/12,5 mg so rdeče in bele, ovalne, dvoslojne, z vtisnjenim znakom podjetja in kodno številko 'H8'.
MicardisPlus 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by MicardisPlus 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Zdravilo MicardisPlus 80 mg/25 mg lahko dajemo enkrat na dan bolnikom, pri katerih krvnega tlaka ne moremo ustrezno uravnati z zdravilom MicardisPlus 80 mg/12,5 mg, ali bolnikom, ki jemljejo telmisartan in hidroklorotiazid posebej in imajo ustaljen krvni tlak.
MicardisPlus 80 mg/25 mg tablets are yellow and white, oval-shaped, two-layer tablets engraved with the company logo and the code 'H9'.
Tablete zdravila MicardisPlus 80 mg/25 mg so rumene in bele, ovalne, dvoslojne, z vtisnjenim znakom podjetja in kodno številko 'H9'.
MicardisPlus fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.
Zdravilo MicardisPlus, fiksna kombinacija (40 mg telmisartana in 12,5 mg hidroklorotiazida), je indicirano za odrasle, pri katerih krvnega tlaka ne moremo ustrezno uravnati s samim telmisartanom.
MicardisPlus fixed dose combination (80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.
Zdravilo MicardisPlus, fiksna kombinacija 80 mg telmisartana in 12,5 mg hidroklorotiazida, je indicirano za odrasle, pri katerih krvnega tlaka ne moremo ustrezno uravnati s samim telmisartanom.
MicardisPlus is also available at the dose strengths 40 mg/12.5 mg and 80 mg/ 12.5 mg
Zdravilo MicardisPlus je na voljo tudi v jakosti 40 mg/12,5 mg in 80 mg/12,5 mg.
MicardisPlus is available in blister packs containing 14, 28, 56, or 98 tablets, or unit dose blister packs containing 28 x 1, 30 x 1 or 90 x 1 tablets
Zdravilo MicardisPlus je na voljo v pretisnih omotih po 14, 28, 56, 84, 98 tablet ali pretisnih omotih za enkratni odmerek po 28 x 1, 30 x 1 ali 90 x 1 tableta.
MicardisPlus is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not controlled enough when telmisartan or is used alone.
Zdravilo MicardisPlus je namenjeno za zdravljenje visokega krvnega tlaka (esencialne hipertenzije) pri odraslih, pri katerih s samim telmisartanom krvnega tlaka ne moremo dovolj uravnavati.
MicardisPlus should not be used in patients with severe renal impairment (creatinine clearance <30 ml/min) (see section 4.3).
Zdravila MicardisPlus ne dajemo bolnikom z močno zmanjšanim delovanjem ledvic (kreatininskim očistkom < 30 ml/min) (glejte poglavje 4.3).
Michała Życzkowskiego 17 31-864 Krakow
31-864 Krakow
Microcrystaline cellulose
mikrokristalna celuloza
Microcrystalline cellulose
celuloza, mikrokristalna
Microcrystalline cellulose
mikrokristalna celuloza,
microcrystalline cellulose
mikrokristalno celulozo,
Microcrystalline cellulose (Avicel PH 102) Sodium starch glycolate (Type A) Poloxamers
mikrokristalna celuloza (Avicel PH 102) natrijev karboksimetilškrob (vrsta A) poloksameri
Microcrystalline cellulose (E460) Calcium hydrogen phosphate, anhydrous Croscarmellose sodium
mikrokristalna celuloza (E460) brezvodni kalcijev hidrogenfosfat premreženi natrijev karmelozat povidon K25
Microcrystalline cellulose (E460) Calcium hydrogen phosphate, anhydrous Maize starch
mikrokristalna celuloza (E460) brezvodni kalcijev hidrogenfosfat koruzni škrob
Microcrystalline cellulose (E460) Lactose anhydrous
mikrokristalna celuloza (E460) brezvodna laktoza
Microcrystalline cellulose and guar gum
celuloza, mikrokristalna in gumi semena cijamopsisa, uprašenega